Drugs /

platinum chemotherapy

Back to Drugs List
Associated Diseases

Overview

Generic Name(s):
platinum-based chemotherapy, platinum-containing chemotherapy, and platinum compound
NCI Definition [1]:
A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for platinum chemotherapy

Platinum chemotherapy has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating platinum chemotherapy, 1 is phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).

PD-L1 Low Expression (TPS = 1-49.999%) and PD-L1 No Expression are the most frequent biomarker inclusion criteria for platinum chemotherapy clinical trials.

Hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in platinum chemotherapy clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Platinum Chemotherapy
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating platinum chemotherapy and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
platinum-based chemotherapy, platinum-containing chemotherapy, platinum compound
NCIT ID [1]:
C1450

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.